DHI SIGNAL · FILING RESEARCH

ABBV Operating cash flow

Operating cash flow at AbbVie rose to $19.0B in fiscal 2025, from $18.8B in 2024.

Net cash provided by operating activities, as filed.

SOURCE: us-gaap:NetCashProvidedByUsedInOperatingActivities · EDGAR CompanyFacts · CIK 1551152 · EDGAR ↗ · FY2021–FY2025 · ANNUAL

FY2025$19.0B
FY2024 $18.8B
HIGH$24.9B FY2022
LOW$18.8B FY2024

History AS FILED · DERIVATION SHOWN WHERE DERIVED

Fiscal yearOperating cash flowChange
FY2025$19.0B+$224M
FY2024$18.8B$-4.0B
FY2023$22.8B$-2.1B
FY2022$24.9B+$2.2B
FY2021$22.8B

Cross-checks touching this measure FROM THE FILING REVIEW

✓ MATCHESfull year results

Every quoted figure reconciles to the filed lines: $61.2 billion against total revenues; $15.1 billion against operating income; $2.36 against diluted earnings per share.

FY2025 10-K · FULL RECONCILIATION →

◐ PARTLYoperating cash flow increase

The quote contains no checkable figures; the lines it references are shown, and nothing on this page confirms or contradicts it. The source sentence carries qualifiers beyond the 40-word quote limit; carried as partly supported.

FY2025 10-K · FULL RECONCILIATION →

✓ CLEANCash conversion stability

OCF ÷ NI ran 4.50× · 4.39× · 4.69× across three years — swing 0.30×, inside the 1.00× threshold.

FY2025 10-K · FULL RECONCILIATION →

✓ CLEANCapital returned vs free cash flow

Capital returned ran 0.71× of free cash flow (threshold 1.00×).

FY2025 10-K · FULL RECONCILIATION →

✓ CLEANStock compensation in cash flow

Share-based compensation is 5.0% of operating cash flow (threshold 15%).

FY2025 10-K · FULL RECONCILIATION →

More SAME DATA, OTHER VIEWS

Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.